RxDoctor Payments Data

Cecil Rambarat, MD

Cardiovascular Disease · Asheville, NCNPI 1790164408

Payments from drug & device makers

$1,554in general payments, 2019–2025

Across 52 payments — averaging $29.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$371
  • Abbott$355
  • Boehringer Ingelheim$216
  • E.r. Squibb & Sons, L.L.C.$213
  • Abiomed$183
  • Amgen$92
  • plus $123 from 6 others

What the payments were for

  • Food & beverage$1,34487%
  • Education$21013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,554 in reported general payments places this provider in the 40th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$198,745
Medicare patients
1,457
Services billed
2,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban311$304,737
EntrestoSacubitril/Valsartan165$147,380
XareltoRivaroxaban78$99,038
Repatha SureclickEvolocumab26$37,059
MultaqDronedarone Hcl16$24,112
JardianceEmpagliflozin25$20,068
Praluent PenAlirocumab11$5,591
NexlizetBempedoic Acid/Ezetimibe11$4,220
Metoprolol Succinate367$4,122
PradaxaDabigatran Etexilate Mesylate13$2,428
Atorvastatin Calcium258$2,364
Midodrine Hcl30$2,147
Amiodarone Hcl50$1,567
Ranolazine ErRanolazine21$1,493
Rosuvastatin Calcium156$1,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$371$304,737311 claims
Johnson & JohnsonXarelto$16$99,03878 claims
Boehringer IngelheimJardiance, Pradaxa$216$22,49738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →